Mylan Receives Approval for Mercaptopurine Tablets USP, 50 mgPITTSBURGH, July 7 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Mercaptopurine Tablets USP, 50 mg. Mercaptopurine Tablets, which are the generic version of Teva Pharmaceuticals' Purinethol^® Tablets, 50 mg, had North American sales of approximately $89.5 million for the 12- month period ended December 2004 according to IMS. The product will be available soon.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

This press release includes statements that constitute "forward-looking statements," including with regard to the availability of Mercaptopurine. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possible negative effects of any interruption of manufacture of the product; uncertainties regarding market acceptance and demand for the product; dependence on third-party suppliers and distributors for raw materials; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Mylan Laboratories Inc.
07/07/2005
CONTACT: Patrick Fitzgerald, Public Relations, or Kris King, Investor Relations of Mylan Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com